Related Experiment Video
Updated: Jun 20, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Anti-angiogenic factor endostatin in osteosarcoma
Hyun-Soo Kim1, Sung-Jig Lim, Yong-Koo Park
1Department of Pathology, School of Medicine, Kyung Hee University, #1 Heoigidong, Dongdaemun-gu, Seoul, Korea.
Abstract:
Neoplastic neovascularization is regulated not only by stimulators, but also by inhibitors of angiogenesis and might be the result of a net balance between the positive and negative regulators. Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not been investigated in patients with osteosarcomas (OSAs). The aim of this study was to determine whether there is a correlation between the expression of ES and clinicopathologic parameters and/or outcomes in patients with OSAs. We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES using immunohistochemistry. Staining was assessed in a semi-quantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells. A sample was defined as ES-positive when 10% or more of the tumor cells were stained positively throughout the tumor core. ES was localized to the cytoplasm of the tumor cells. 32.6% (15/46) of the patients were ES-positive. The expression of ES was positively correlated with tumor size (p = 0.011), histologic grade (p = 0.034), stage (p = 0.025), and distant metastasis (p = 0.036). Our results suggest that the expression of ES is increased in OSA, and ES may be used as a prognostic marker in patients with OSAs.
Insights
Endostatin (ES), an angiogenesis inhibitor, is upregulated in osteosarcomas (OSAs). Increased ES expression correlates with larger tumor size, higher grade, advanced stage, and metastasis, suggesting its potential as a prognostic marker for OSAs.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Neoplastic neovascularization involves a balance of pro-angiogenic and anti-angiogenic factors.
- Endostatin (ES) is a known potent inhibitor of angiogenesis.
- The expression and clinical significance of Endostatin in osteosarcomas (OSAs) remain largely uninvestigated.
Purpose of the Study:
- To investigate the expression of Endostatin (ES) in osteosarcoma (OSA) tissues.
- To determine the correlation between ES expression and clinicopathologic parameters and patient outcomes in OSAs.
Main Methods:
- Tissue microarrays were constructed from 46 osteosarcoma (OSA) cases.
- Immunohistochemistry was employed to analyze Endostatin (ES) expression.
- Semi-quantitative scoring assessed the proportion of positive tumor cells; 10% positivity defined ES-positive cases.
Main Results:
- Endostatin (ES) expression was detected in the cytoplasm of OSA tumor cells.
- 32.6% (15/46) of the osteosarcoma (OSA) cases were found to be ES-positive.
- ES expression showed a significant positive correlation with tumor size (p=0.011), histologic grade (p=0.034), stage (p=0.025), and distant metastasis (p=0.036).
Conclusions:
- The expression of Endostatin (ES) is increased in osteosarcomas (OSAs).
- Elevated ES expression is associated with adverse clinicopathologic features in OSAs.
- Endostatin (ES) may serve as a valuable prognostic marker for patients diagnosed with osteosarcomas (OSAs).
